No seroconversion in a retrospective study analyzing <scp>QuantiFERON TB</scp>‐gold testing in pediatric psoriasis and hidradenitis suppurativa patients taking biologic therapy at an academic center in <scp>New York City</scp>-Reference-Cited by-同舟云学术

No seroconversion in a retrospective study analyzing QuantiFERON TB‐gold testing in pediatric psoriasis and hidradenitis suppurativa patients taking biologic therapy at an academic center in New York City

Published:2024-02-27 Issue:4 Volume:41 Page:733-735
ISSN:0736-8046
Container-title:Pediatric Dermatology
language:en
Short-container-title:Pediatric Dermatology

Author:

Katsiaunis Apostolos¹^ORCID,Conway Jade²,Lipner Shari R.³^ORCID

Affiliation:

1. Tufts University School of Medicine Boston Massachusetts USA

2. School of Medicine, New York Medical College Valhalla New York USA

3. Department of Dermatology Weill Cornell Medicine New York New York USA

Abstract

AbstractGuidelines are inconsistent regarding annual QuantiFERON® TB Gold (QFT) tests in children taking biologics for dermatological conditions, and there is limited research on seroconversion, especially in regions with high tuberculosis (TB) prevalence. A retrospective review of pediatric patients taking biologic treatment for psoriasis or hidradenitis suppurativa (HS) who had one baseline and at least one follow‐up QFT test was conducted to assess for seroconversion during treatment. Thirty‐two patients were included, with no instances of seroconversion. These findings suggest that routine annual TB rescreening for pediatric patients taking biologic therapy for dermatologic conditions may not be necessary without additional TB exposure risks or symptomatology.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pde.15577

Reference6 articles.

1. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

2. State & Local Data [Internet]. Centers for Disease Control and Prevention;2022[cited 2023 Oct 13]. Available from:https://www.cdc.gov/tb/statistics/reports/2022/state_local_data.htm.